

Did we see it coming? An Evaluation of the Swedish Early Awareness and Alert System

Irene Eriksson^{1,2}, Mia von Euler^{1,3,4}, Rickard E. Malmström^{1,3}, Brian Godman^{3,5,6}, Björn Wettermark^{1,2}

¹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

²Department of Healthcare Development, Stockholm County Council, Stockholm, Sweden

³Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden

⁴Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

⁵Health Economics Unit, University of Liverpool Management School, Liverpool, United Kingdom

⁶Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, United Kingdom

Corresponding Author

Irene Eriksson; Department of Medicine Solna, Karolinska Institutet; Clinical Epidemiology Unit T2, Karolinska University Hospital; Stockholm, SE-171 76, Sweden. Email: irene.eriksson@ki.se

(Accepted for publication Applied Health Economics and Health Policy – Please keep Confidential)

Abstract

Purpose

Early awareness and alert (EAA) systems have been established in many countries but evidence on their ability to accurately prioritize new medicines (for early assessment) is limited. The purpose of this study is to assess whether the Swedish EAA System identified

and prioritized (i.e. produced early assessment reports for) new medicines that would go on to have a substantial economic impact.

Methods

We adapted a study design commonly used in the assessment of diagnostic test accuracy. The prioritization made by the Swedish EAA System prior to marketing authorization comprised the *index test* and national drug sales data in the second year post-authorization served as the *reference standard*. All initial marketing authorization applications for medicinal products processed by the European Medicines Agency (EMA) between 2010 and 2015 (*study population*) were classified using the index test and the reference standard.

Results

Two hundred and fifty-three new medicinal products processed by EMA comprised the study population. Of these, 71 were prioritized by the Swedish EAA System and 21 were classified as having a substantial economic impact. The sensitivity and positive predictive value were 76.2% and 22.5%, respectively. Subgroup analyses showed that the accuracy of prioritization, in terms of sensitivity, was 100% for antineoplastic/immunomodulating agents.

Conclusions

The Swedish EAA System identified all new medicines that would go on to have a substantial economic impact and prioritized most of these medicines. Our findings provide reassurance to decision makers who rely on the outputs of the Swedish EAA System to keep informed about new medicines. Moreover, this study also provides valuable insights to stakeholders willing to establish and/or evaluate their own EAA activities and systems.

Key points for decision makers

1. Of new medicines authorized by the European Medicines Agency from 2010 to 2015, only 10% exceeded sales of €4M (0.1% of total pharmaceutical expenditure per year in Sweden) in the second year on market.
2. Over the first years of work since its establishment in 2010, the Swedish EAA System identified all new medicines that would go on to have a substantial economic impact in the first two years post-authorization. For most of these medicines an early assessment report was provided to decision makers ahead of the marketing authorization.

1. Introduction

As already stretched healthcare budgets are put under additional pressure with the introduction of new expensive medicines (1-4), payers are increasingly seeking greater value for their money (5-10). In addition, timely access to new and meaningfully better medicines to improve patient outcomes is considered a priority in many countries (11). The early identification of new emerging technologies prior to their introduction can enable timely assessments to be undertaken and activities set up to facilitate rational uptake and utilization. However, scrutinizing the research and development pipeline to identify medicines that may impact healthcare is notoriously difficult and requires considerable expertise. Horizon scanning systems (also known as early awareness and alert systems) (12) can provide the necessary support to health technology assessment (HTA) bodies and payers.

Early awareness and alert (EAA) activities are now recognized as a key element in processes for the introduction of new medicines (7, 13). In view of this, the structure, processes, outputs, and impact of an EAA system should be regularly evaluated and tailored to meet customer needs (14, 15). It is reasonable to assume that an established EAA system carries out evaluations of its work as part of improvement initiatives. In Sweden, for example, feedback from stakeholder interviews was used to improve both the process and outputs of the Swedish EAA system (16). However such evaluations are typically internal and of a qualitative nature. Furthermore, they may not be readily accessible to wider audiences, thereby hampering the opportunity to learn from experiences across systems. To date, EAA systems with published evaluations include the United Kingdom's National Institute for Health Research Horizon Scanning Research & Intelligence Centre (UK NIHR HSRIC) (17-19), the Austrian Horizon Scanning Programme in Oncology (20), and the United States Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System (21).

The Swedish EAA System has been carrying out EAA activities at the national level since 2010. It was established to support the long-term planning of the county councils and to optimize the readiness of the healthcare system to the introduction of new medicines. A detailed description of the Swedish EAA System is available elsewhere (22). Both regional and national decision makers use the outputs of the system—including early assessment

reports produced for prioritized medicines—to keep informed about and to prepare for the introduction of new medicines. The purpose of this study is to assess whether the Swedish EAA System identified and prioritized new medicines that would go on to have a substantial economic impact.

2. Methods

2.1. Study design

We adapted a study design commonly used in the assessment of diagnostic test accuracy to compare an index test's classification of a target condition with a reference standard's classification (17). For the purpose of our assessment, the prioritization (i.e. selection for early assessment) made by the Swedish EAA System comprised the *index test* and national sales data served as the *reference standard*. All initial marketing authorization applications for medicinal products processed by the European Medicines Agency (EMA) from 1 January 2010 to 31 December 2015 (*study population*) were classified using the index test and the reference standard. New indications of already authorized medicinal products (extensions of indications) were not included. The end date for selecting the study population was chosen to provide at least two years of follow-up sales data on all medicines following marketing authorization.

2.2. Study population

To compile the study population, all European Public Assessment Reports on medicines, authorized or refused, were obtained from the EMA website (23). We also retrieved information on all withdrawals of initial marketing authorization applications. All medicines processed from 1 January 2010 to 31 December 2015 were included, regardless if they were authorized or refused by EMA, or withdrawn by the manufacturer.

We excluded generics, biosimilars, vaccines, as well as known active substances with a history of use in clinical practice for the applied indication (e.g. asparaginase [Spectrila] for use in acute lymphoblastic leukaemia; metformin hydrochloride/saxagliptin hydrochloride [Komboglyze] for use in type 2 diabetes). Finally, we removed duplicates, such as multiple

and informed consent applications. The selection process for the study population is presented in Figure 1.

2.3. Index test

The Swedish EAA System identifies and prioritizes new medicines and new indications of already approved medicines that may have an impact on the health care system (22). The following criteria are considered in the filtration and prioritization steps: the patient population size; burden of disease; budget impact; anticipated clinical benefits; level of innovation; organizational impact; impact on treatment guidelines; safety aspects; level of interest from media and patient organizations; anticipated sub-optimal market uptake; and relevance from a legal, ethical and/or political aspect. For a prioritized medicine, an early assessment report—the starting point for the national process for managed introduction and follow-up of new medicines—is produced prior to regulatory approval. In addition to early assessment reports, the Swedish EAA System produces the following outputs: a horizon scanning database of identified new and emerging medicines, a list of prioritized medicines (including already produced as well as planned early assessment reports), and quarterly newsletters. Per agreement with its customers (i.e. the New Therapies [NT] Council and individual counties) the Swedish EAA System seldom produces early assessment reports for medicines with an existing mechanism of action for an indication or for orphan medicines.

The decision to prioritize a new medicine (i.e. to produce an early assessment report for a new medicine) comprised the index test. We retrieved all early assessment reports produced from 1 January 2010 to 31 December 2015. Reports on extensions of indications of already authorized medicinal products were excluded (e.g. apixaban: Eliquis was only included once with no distinction given to its multiple indications). Furthermore, we excluded reports for medicines processed by EMA before 1 January 2010 or after 31 December 2015.

2.4. Reference standard

National drug sales data were used to derive the reference standard in our study. The eHealth Agency records complete pharmaceutical sales data from all pharmacies, retailers, and wholesalers in Sweden (24). We obtained aggregate monthly sales data on hospital sales

and dispensed prescription medicines in ambulatory care (reimbursed expenditure and patient co-payment) from 1 January 2010 to 31 December 2017.

For the main analyses we calculated sales in the second year (i.e. the second 12-month period following the date of EMA marketing authorization). We also conducted sensitivity analyses based on sales in the third year restricting the study population to those medicines with sufficient follow-up time.

As total annual pharmaceutical sales in Sweden have been approximately €4 billion (EUR:SEK = 9.5, average 2015–2017) for the past few years, we chose 0.1% of that value (€4 million in sales per year) as a nominal threshold point (cut-off). A new medicine that exceeded this threshold in its second year on market was classified as having a substantial economic impact on the healthcare system (positive reference test). In addition, recognizing the arbitrary nature of the chosen threshold, we conducted sensitivity analyses exploring how varying the cut-off would change our results.

2.5. Statistical analyses

Baseline characteristics were analyzed using descriptive statistics. Categorical data were reported as proportions and continuous data as medians with interquartile ranges (IQRs). The accuracy of prioritizations was summarized in a contingency table. Outcome statistics were reported as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with exact binomial 95% confidence intervals. Sensitivity was defined as the proportion of prioritized medicines among all medicines exceeding the sales threshold. Specificity was defined as the proportion of non-prioritized medicines among all medicines below the sales threshold. PPV was defined as proportion of medicines exceeding the sales threshold among all prioritized medicines. NPV was defined as the proportion of medicines below the threshold among all non-prioritized medicines.

In addition to varying the cut-off for the reference standard (€2–8 million in annual sales) and timing of sales (sales in the third year on the market), we conducted additional analyses to restrict the study population to the following subgroups: new active substances; orphan

medicines; and antineoplastic and immunomodulating agents (based on the Anatomical Therapeutic Chemical [ATC] classification).

3. Results

During the study period (2010–2015) we identified 462 medicinal products that were authorized or refused by EMA and an additional 64 medicinal products whose initial authorization application was withdrawn by the manufacturer. After applying our exclusion criteria, a study population of 253 medicinal products was yielded (Fig 1). Most commonly—in almost three out of four cases—the excluded medicines were either generics or known active substances intended for use in an already approved indication. All 253 medicinal products were identified by the Swedish EAA System.

<<<Fig 1 – Study population and early assessment report selection flowchart>>>

<<<Fig 1 Notes – EPAR European public assessment reports; MA marketing authorization; EAA early awareness and alert; NAS new active substance; KAS known active substance>>>

During the study period, 104 early assessment reports were published (Fig 1). Of these, 33 reports were excluded from our analyses (Online Resource 1); most frequently for covering extensions of indications of already authorized medicinal products. This left us with 71 prioritized medicines (positive index test).

Table 1 provides a description of the total study population and the prioritized medicines. The majority of the medicinal products processed by EMA were classified as new active substances (86%) and/or were granted marketing authorization (83%); among the medicines prioritized by the EAA System these proportions were slightly higher at 93% and 90%, respectively. Antineoplastic and immunomodulating agents were the most common group of medicines overall (29%) and among the prioritized medicines (51%). The early assessment reports were published around three months ahead of the date of marketing authorization (median [IQR] number of days 87 [40, 187]).

<<<Table 1 – Characteristics of the study population and the medicines prioritized by the Swedish EEA System >>>

In total, based on analyses of sales data we classified 21 new medicinal products as having a substantial economic impact on the healthcare system (positive reference test). An overview of these medicines is provided in Table 2.

<<<Table 2 – Medicinal products with substantial sales in Sweden in the second year on market>>>

A tabular comparison of the prioritizations made by the EAA System and the economic impact is provided in Table 3 with corresponding measures of prioritization accuracy in Table 4. The EAA System prioritized 16 medicinal products for a sensitivity of 76%. The other prioritized medicines (n=55) were among the 232 medicinal products that did not exceed €4 million in sales (corresponding to a specificity of 76%).

<<<Table 3 – Tabulation by prioritization made by the EAA System and the economic impact >>>

<<<Table 4 – Measures of prioritization accuracy >>>

Subgroup and sensitivity analyses were generally in line with the main analyses. The accuracy of prioritization, in terms of sensitivity, was highest for antineoplastic/immunomodulating agents (100%) and new active substances (76%). Conversely, the lowest accuracy of prioritization was observed when using the lower sales threshold (65%). Detailed data are presented in Online Resource 2.

4. Discussion

We found that the Swedish EAA System identified all new medicines that would go on to have a substantial economic impact and prioritized (i.e. produced an early assessment report) for most of these medicines. The few non-prioritized medicines whose sales exceeded the threshold were identified by the system but not selected for an early assessment report because similar medicines had been already prioritized and/or marketed earlier (e.g. Sovaldi was already selected for a report prior to Daklinza and Harvoni, thus the

latter two were not prioritized). Overall, these findings indicate that decision makers in Sweden have been accurately informed about impending new medicines prior to their launch. This early awareness allowed, for example, for special activities to be set up to facilitate rational and cost-effective introductions of new medicines into clinical practice either at the regional (25, 26) or national (27) level. Notably, all new medicines comprising the study population were identified by the Swedish EAA System. For many of the non-prioritized medicines, for which no early assessment report was produced, information was summarized and disseminated in other ways (e.g. a list of all identified orphan medicines is regularly updated and provided to both regional and national stakeholders).

Potential economic impact is however just one of many criteria that the Swedish EAA System weighs together in the decision to prioritize a medicine. For example, factors contributing to the prioritization of obesity medicines (e.g. phentermine/topiramate [Qsiva]), included the patient population size, safety aspects, and anticipated media interest. New medicines that are seen as innovative ways of treating a disease are also prioritized; for example bezlotoxumab (Zinplava) as passive immunization against *C. difficile* toxins, ipilimumab (Yervoy) for treatment of advanced melanoma, olaparib (Lynparza) as maintenance treatment of platinum-sensitive recurrent BRCA-mutated ovarian cancer, and ranibizumab (Lucentis) for treatment of visual impairment due to diabetic macular oedema were primarily prioritized for this reason (16). The fact that the sales figures do not necessarily reflect all prioritization criteria explains the relatively low PPV (range: 12–35%) – i.e. fewer than 1 in 3 prioritized medicines went on to have a substantial economic impact. The prioritization of such medicines may however be equally important. For example, new innovative ways to treat diseases may have systemic effects on the delivery of healthcare services and require preparation ahead of the introduction. Consequently, given the holistic approach to prioritization employed by the Swedish EAA System combined with their efforts to improve efficiency (e.g. the Swedish EAA System typically does not prioritize medicines with an existing mechanism of action for an indication or orphan medicines), it is difficult to propose revisions to their ways of working that would lead to improved sensitivity and PPV in prioritization of the medicines with eventual substantial economic impact.

As a byproduct of our analyses, we obtained an overview of all new medicines assessed by EMA during the period 2010–2015. We identified 217 new active substances that were

submitted to EMA during these years. One fourth of these were in the oncology/immunology field, and a considerable number of medicinal products were also introduced for metabolic (diabetes and rare diseases) and infectious diseases. Correspondingly, over a half of the medicines prioritized by the Swedish EAA System were in oncology or immunology, which is similar to outputs from other EAA systems (19, 20).

Apart from providing an assessment of how the Swedish EAA System has performed so far in identifying and prioritizing new medicines that would have a substantial economic impact, this study also contributes to the scarce literature on the evaluation of EAA activities and systems. As outlined in the EuroSCAN methods toolkit, evaluation is an important element of an established EAA system (14). However, few reports on such evaluations have been published to date (15, 17-21, 28). This could possibly be explained by lack of scientific interest and involvement, but also by methodological challenges, including the definition of a reference standard to be used for comparisons. The ideal reference standard should be able to reflect the prioritization criteria used by an EAA system but it may not be feasible to obtain a single measure that captures the criteria in their entirety (e.g. the Swedish EAA System's prioritization criteria range from "potential to affect treatment costs" to "legally, ethically, or politically interesting"). **In addition to sales data we also considered using other variables, including the size of patient population, HTA recommendation, and level of innovation. Reliable estimation of the size of patient population however proved to be difficult primarily due to lack of data on patient counts, particularly for narrow indications. Results of HTA are only available for medicines that are included in the pharmaceutical benefits scheme, but many of those prioritized are intended for hospital use only for which, during the study period, no national appraisal was made. Finally, we also explored approaches to measure the level of innovation but found no universally accepted standard that could be used in our study.**

Using sales data as a reference standard appears to capture both directly and indirectly some of the prioritization criteria used, including the size of patient population, potential to clinically improve patient outcomes, and potential to affect treatment costs. In addition, sales objectively reflect which new medicines are actually adopted in clinical practice. However, we encountered a number of limitations with using sales data as a reference standard. We acknowledge that our choice of the timing of sales (i.e. second and third year)

and the cut-off value are pragmatic approaches to operationalize our analyses. Measuring sales early in the product life cycle may underestimate the number of impactful medicines. Reasons for this include medicines with slower uptake and medicines initially marketed in narrower indications (e.g. non-vitamin K antagonist oral anticoagulants). We believe, however, that early sales are well-suited to capture medicines with a strong immediate impact that warrant preparedness by the healthcare system. The prioritization accuracy was also sensitive to the cut-off values used in our analyses. In the main analyses we used a pre-specified threshold of approximately 0.1% of yearly total pharmaceutical sales. While this may not seem like a high level, in absolute terms the impact can be substantial, especially for specialist medicines used in a limited number of hospitals. Moreover, the aggregate nature of the sales data does not allow us to attribute sales to a given indication for medicinal products that are used in multiple indications. We also excluded all new vaccines from our analyses as no complete sales data were available due to separate distribution chains. While no vaccines were prioritized during the study period, more recently, in 2017, the Swedish EAA system prioritized herpes zoster vaccine Shingrix (29). Recent progress in vaccine research and development may translate into an increase in breakthrough therapies (30) that warrants the inclusion of vaccines in future evaluations. Finally, there is a possibility that an early assessment report could have influenced sales as the two measures are not independent (e.g. taking into account the information provided by the Swedish EAA System, the NT Council or individual counties may have recommended not to use a given medicine). Including information on whether there was a positive or negative recommendation issued either by the NT-Council or individual counties into our analyses would be a possible way to address this, however the national level recommendations were not provided until recently and, moreover, it was not possible to systematically collect data on all decisions taken at a county level.

This study was carried out as an independent evaluation of the Swedish EAA System. While all authors have knowledge of this particular EAA system, and the role of EAA activities in the process of introduction of new medicines in general, none of the authors has been involved in decision making on which medicines to prioritize. Furthermore, our study is the first evaluation of an EAA system to use sales data as a reference standard to define which new medicines impacted the healthcare system. Despite the aforementioned limitations of such

a one-dimensional measure, we believe it is nonetheless of value to explore its utility and share the results of this study with stakeholders both in Sweden and internationally.

To summarize, our findings provide reassurance to decision makers who rely on the outputs of the Swedish EAA System. Moreover, this study also contributes to the scarce literature on evaluations of EAA activities and systems thus provides valuable insights to stakeholders willing to establish and/or evaluate their own EAA activities.

Acknowledgements

The authors wish to thank the horizon scanning working group (Anna Bergkvist Christensen, Marie Persson, Morgan Edström, Anna Lindhé, and Helena Ramström) for answering queries and providing the authors with all information necessary for the evaluation of the Swedish EAA System, although they had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit the manuscript for publication; Maria Juhasz Haverinen for help with the acquisition of drug sales data; and Tomas Salmonson for reading the manuscript and for helpful discussions.

Data availability statement

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Author contribution

IE and BW designed the study. IE managed and analyzed the data. All authors contributed to the interpretation of the data. IE and BW drafted the manuscript, and all authors revised it critically for important intellectual content. All authors approved the version to be submitted for publication. IE had full access to all data and is responsible for the integrity and the accuracy of the data analysis.

Compliance with ethical standards

No ethical approval was required for this study.

Conflict of interest

IE, MvE, REM, BG, and BW have no conflicts of interest to declare.

Funding

This study was funded by the Swedish Association of Local Authorities and Regions. The funder had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit the manuscript for publication.

References

1. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. *The Lancet Oncology*. 2014;15(3):e112-8.
2. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the Market for Anticancer Drugs. *The journal of economic perspectives : a journal of the American Economic Association*. 2015;29(1):139-62.
3. Goulart BH. Value: The Next Frontier in Cancer Care. *The oncologist*. 2016;21(6):651-3.
4. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS medicine*. 2016;13(5):e1002032.
5. Morel T, Aricx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. *Orphanet journal of rare diseases*. 2013;8:198.
6. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. *Social science & medicine*. 2015;124:39-47.
7. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert review of clinical pharmacology. 2015;8(1):77-94.
8. Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring Registries at Italian Medicines Agency: Fostering Access, Guaranteeing Sustainability. *International journal of technology assessment in health care*. 2015;31(4):210-3.
9. Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. *Applied health economics and health policy*. 2017;15(3):307-21.
10. Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. *Frontiers in pharmacology*. 2017;8:171.

11. Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, et al. Accelerated access to innovative medicines for patients in need. *Clinical pharmacology and therapeutics*. 2014;96(5):559-71.
12. HTA Glossary 2018. Available from: www.htaglossary.net.
13. World Health Organization. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research: WHO Regional Office for Europe; 2015.
14. Simpson S, EuroScan International Network. A toolkit for the identification and assessment of new and emerging health technologies. Technical Report. Birmingham, UK: University of Birmingham, 2014.
15. Lepage-Nefkens I, Douw K, Mantjes G, de Graaf G, Leroy R, Cleemput I. Horizon Scanning for Pharmaceuticals: proposal for the BeNeLuxA collaboration. 2017.
16. Personal communication. Anna Bergkvist Christensen, 5 April, 2018. 2018.
17. Simpson S, Hyde C, Cook A, Packer C, Stevens A. Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system. *International journal of technology assessment in health care*. 2004;20(3):381-4.
18. Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. *International journal of technology assessment in health care*. 2007;23(3):324-30.
19. Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. *International journal of technology assessment in health care*. 2012;28(3):308-14.
20. Nachtnebel A, Breuer J, Willenbacher W, Bucsics A, Krippel P, Wild C. Looking Back on 5 Years of Horizon Scanning in Oncology. *International journal of technology assessment in health care*. 2016;32(1-2):54-60.
21. Duda N, Fleming C, Kirwan B, Roff B, Rich E. Evaluation of the AHRQ Healthcare Horizon Scanning System. *Mathematica Policy Research*, 2016.
22. Eriksson I, Wettermark B, Persson M, Edstrom M, Godman B, Lindhe A, et al. The Early Awareness and Alert System in Sweden: History and Current Status. *Frontiers in pharmacology*. 2017;8:674.
23. EMA. EMA 2018. Available from: www.ema.europa.eu.
24. Swedish eHealth Agency. 2018. Available from: <https://www.ehalsomyndigheten.se/other-languages/english/>.
25. Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. *European journal of clinical pharmacology*. 2018;74(5):663-70.
26. Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. *European journal of clinical pharmacology*. 2018;74(2):219-26.
27. Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. *European journal of clinical pharmacology*. 2018.
28. Douw K, Vondeling H. Selecting new health technologies for evaluation: can clinical experts predict which new anticancer drugs will impact Danish health care? *Social science & medicine*. 2007;64(2):283-6.

29. The Swedish Early Awareness and Alert System. Shingrix early assessment report 2017. Available from:

http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Shingrix-tidig-bedomningsrapport170519.pdf.

30. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nature reviews Drug discovery. 2018;17(4):261-79.

Tables

Table 1 – Characteristics of the study population and the medicines prioritized by the Swedish EEA System

Table 2 – Medicinal products with substantial sales in Sweden in the second year on market

Table 3 – Tabulation by prioritization made by the EAA System and the economic impact

Table 4 – Measures of prioritization accuracy

Table 1

Characteristic	Study population*		EAA System prioritized medicinal products	
	<i>n</i>	%	<i>n</i>	%
<i>Medicinal products</i>				
New AS [#]	217	86	66	93
Known AS	36	14	5	7
Total	253	100	71	100
<i>MA status</i>				
Authorized	210	83	64	90
Refused	14	6	4	6
Withdrawn	29	11	3	4

Characteristic	Study population*		EAA System prioritized medicinal products	
	<i>n</i>	%	<i>n</i>	%
<i>Orphan</i>				
Yes	51	20	13	18
No	173	68	55	77
Missing	29	11	3	4
<i>Year</i>				
2010	21	8	9	13
2011	37	15	10	14
2012	34	13	14	20
2013	53	21	13	18
2014	52	21	12	17
2015	56	22	13	18
<i>TA based on the ATC classification system</i>				
Alimentary tract and metabolism	29	11	5	7

Characteristic	Study population*		EAA System prioritized medicinal products	
	<i>n</i>	%	<i>n</i>	%
Blood and blood forming organs	18	7	2	3
Cardiovascular system	15	6	5	7
Dermatologicals	5	2	1	1
Genito-urinary system and sex hormones	7	3	1	1
Systemic hormonal preparations, excluding sex hormones and insulins	1	0	0	0
Antiinfectives for systemic use	26	10	4	6
Antineoplastic and immunomodulating agents	66	26	34	48
Musculo-skeletal system	6	2	3	4
Nervous system	19	8	4	6
Antiparasitic products, insecticides and repellents	1	0	0	0
Respiratory system	10	4	5	5
Sensory organs	6	2	1	1
Various	12	5	2	3
Missing	32	13	4	6

AS active substance; ATC anatomical therapeutic chemical; EAA early awareness and alert; MA marketing authorization

* Medicinal products authorized or refused by EMA and withdrawals of initial marketing authorization applications
 #A chemical substance not previously authorized as a medicinal product in the European Union; or an isomer, mixture of isomers, a complex or derivative or salt of a chemical substance previously authorized as a medicinal product in the Union but significantly differing in properties with regard to safety and efficacy from that chemical substance previously authorized

Table 2

Medicinal product*	TA	ATC	Common name	EMA authorization date	Prioritization date#
Elocta; Swedish Orphan Biovitrum	Hemophilia A	B02BD02	efmoroctocog alfa	2015-11-19	.
Opsumit; Actelion	Hypertension , Pulmonary	C02KX04	macitentan	2013-12-20	.
Betmiga; Astellas	Urinary Bladder, Overactive	G04BD12	mirabegron	2012-12-20	2012-08-24
Triumeq; ViiV Healthcare	HIV Infections	J05AR13	abacavir sulfate/ dolutegravir sodium / lamivudine	2014-09-01	.
Daklinza; Bristol- Myers Squibb	Hepatitis C, Chronic	J05AX14	daclatasvir	2014-08-22	.
Sovaldi; Gilead	Hepatitis C, Chronic	J05AX15	sofosbuvir	2014-01-16	2014-01-24

Medicinal product*	TA	ATC	Common name	EMA authorization date	Prioritization date*
Harvoni; Gilead	Hepatitis C, Chronic	J05AX65	ledispavir/ sofosbuvir	2014-11-17	.
Yervoy; Bristol- Myers Squibb	Melanoma	L01XC11	ipilimumab	2011-07-13	2010-08-19
Opdivo; Bristol- Myers Squibb	Melanoma	L01XC17	nivolumab	2015-06-19	2015-05-6
Keytruda; MSD	Melanoma	L01XC18	pembrolizuma b	2015-07-17	2015-01-21
Zelboraf; Roche	Melanoma	L01XE15	vemurafenib	2012-02-17	2012-02-2
Imbruvica; Janssen- Cilag	MCL; CLL	L01XE27	ibrutinib	2014-10-21	2014-08-28
Kyprolis; Amgen	Multiple Myeloma	L01XX45	carfilzomib	2015-11-19	2015-10-7
Xtandi; Astellas	Prostatic Neoplasms	L02BB04	enzalutamide	2013-06-21	2013-01-29
Zytiga; Janssen- Cilag	Prostatic Neoplasms	L02BX03	abiraterone	2011-09-5	2011-10-18

Medicinal product*	TA	ATC	Common name	EMA authorization date	Prioritization date#
Gilenya; Novartis	Multiple Sclerosis	L04AA27	fingolimod	2011-03-17	2010-12-22
Otezla; Celgene	Arthritis, Psoriatic; Psoriasis	L04AA32	apremilast	2015-01-15	2014-12-09
Entyvio; Takeda	Colitis, Ulcerative; Crohn Disease	L04AA33	vedolizumab	2014-05-22	2014-02-20
Cosentyx; Novartis	Psoriasis	L04AC10	secukinumab	2015-01-15	2014-12-09
Tecfidera; Biogen	Multiple Sclerosis	N07XX09	dimethyl fumarate	2014-01-30	2013-02-15
Eylea; Bayer	Wet Macular Degeneration	S01LA05	aflibercept	2012-11-22	2012-05-18

ATC anatomical therapeutic chemical; CLL chronic lymphocytic leukemia; EMA European Medicines Agency; MCL mantle cell lymphoma; TA therapeutic area

*Medicinal products with sales >€4 million in the second year on the market

#Date of EAA Assessment report publication

Table 3

		Sales Impact		
		>€4 million	≤€4 million	Total
EAA System Prioritization	Prioritized	18	55	73
	Not prioritized	3	177	180
	Total	21*	232	253

EAA early awareness and alert

*Two direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C were re-classified positive on the index test since they were covered by a national program for managed introduction of DAAs

Table 4

Measure	%	CI (95%)	
Sensitivity	85.7	63.7	97.0
Specificity	76.3	70.3	81.6
PPV	24.7	15.3	36.1
NPV	98.3	95.2	99.7

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Online Resource 1

Medicinal product	TA	ATC	Common name	Prioritization date*	Reason for exclusion
Xifaxan	Hepatic encephalopathy	A07AA11	rifaximin	2012-08-24	Not EMA
Uptravi	Hypertension, Pulmonary	B01AC27	selexipag	2015-10-7	After study period
Pradaxa	Atrial Fibrillation	B01AE07	dabigatran etexilate	2009-11-11	Indication extension
Xarelto	Atrial Fibrillation	B01AF01	rivaroxaban	2012-03-13	Indication extension
Xarelto	Deep Vein Thrombosis; Pulmonary Embolism	B01AF01	rivaroxaban	2012-04-18	Indication extension
Xarelto	Acute Coronary Syndrome	B01AF01	rivaroxaban	2012-08-24	Indication extension
Eliquis	Atrial Fibrillation	B01AF02	apixaban	2012-03-13	Indication extension
Procoralan	Chronic Heart Failure	C01EB17	ivabradine	2012-01-31	Indication extension
Samsca	Inappropriate ADH Syndrome	C03XA01	tolvaptan	2010-09-29	Before study period
Cialis	Benign Prostatic Hyperplasia	G04BE08	tadalafil	2012-09-25	Indication extension

Medicinal product	TA	ATC	Common name	Prioritization date	Reason for exclusion
Avodart	Prostatic Neoplasms	G04CB02	dutasteride	2011-04-5	Indication extension
Cokiera	Hepatitis C, Chronic	J05	dasabuvir / ombitasvir / paritaprevir / ritonavir	2014-11-12	After study period [#]
Abraxane	Pancreatic Neoplasms	L01CD01	paclitaxel	2013-12-9	Indication extension
Avastin	Ovarian Neoplasms	L01XC07	bevacizumab	2011-11-2	Indication extension
Cyramza	Colorectal Neoplasms	L01XC21	ramucirumab	2015-09-30	Indication extension
Cyramza	Carcinoma, Non-Small-Cell Lung	L01XC21	ramucirumab	2015-10-13	Indication extension
Opdivo	Carcinoma, Non-Small-Cell Lung	L01XC21	nivolumab	2015-06-25	Indication extension
Portrazza	Carcinoma, Non-Small-Cell Lung	L01XC22	necitumumab	2015-10-13	After study period
Afinitor	Breast Neoplasms	L01XE10	everolimus	2012-10-18	Indication extension

Medicinal product	TA	ATC	Common name	Prioritization date	Reason for exclusion
Tagrisso	Carcinoma, Non-Small-Cell Lung	L01XE35	osimertinib	2015-12-16	After study period
Zytiga	Prostatic Neoplasms	L02BX03	abiraterone acetate	2013-01-16	Indication extension
Soliris	Hemoglobinuria, Paroxysmal	L04AA25	eculizumab	2010-12-22	Before study period
Xeljanz	Arthritis, Rheumatoid	L04AA29	tofacitinib	2012-10-22	After study period
Zinbryta	Multiple Sclerosis	L04AC01	daclizumab	2015-10-22	After study period
Zurampic	Hyperuricemia	M04AB05	lesinurad	2015-12-2	After study period
Palexia Depot	Pain	N02AX06	tapentadol	2010-12-22	Not EMA
Sativex	Multiple Sclerosis	N02BG10	cannabinoids	2012-04-20	Not EMA
Seroquel XR	Depressive Disorder, Major	N05AH04	quetiapine	2010-07-12	Indication extension
Seroquel XR	Anxiety Disorders	N05AH04	quetiapine	2010-09-16	Indication extension

Medicinal product	TA	ATC	Common name	Prioritization date*	Reason for exclusion
Onbrez Breezhaler	Pulmonary Disease, Chronic Obstructive	R03AC18	indacaterol	2010-05-12	Before study period
Macugen	Macular Edema	S01LA03	pegaptanib	2011-05-20	Indication extension
Lucentis	Macular Edema	S01LA04	ranibizumab	2010-10-27	Indication extension
Lucentis	Macular Edema	S01LA04	ranibizumab	2011-09-6	Indication extension

ATC anatomical therapeutic chemical; EMA European Medicines Agency; TA therapeutic area

*Date of Early Assessment Report

#Withdrawn by manufacturer

Online Resource 2

Table 3: Sales year 3

Sales Impact

		>€4 million	≤€4 million	Total
EAA System Prioritization	Prioritized	18	39	57
	Not prioritized	6	134	140
	Total	24	173	197

EAA early awareness and alert

Table 4 - Sales year 3

Statistic		95% CIs	
		Sensitivity	75.0
Specificity	77.5	70.5	83.5
PPV	31.6	19.9	45.2
NPV	95.7	90.9	98.4

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Table 3: NAS – only NAS are included

		Sales Impact		
		>€4 million	≤€4 million	Total
EAA System Prioritization	Prioritized	18	50	68
	Not prioritized	3	146	149
	Total	21	196	217

EAA early awareness and alert

Table 4 - only NAS are included

Statistic		95% CIs	
		Sensitivity	85.7
Specificity	74.3	67.8	80.4
PPV	26.5	16.5	38.6
NPV	98.0	94.2	99.6

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Table 3: Orphan

		Sales Impact		
		>€4 million	≤€4 million	Total
EAA System Prioritization	Prioritized	2	11	13
	Not prioritized	1	37	38
	Total	3	38	51

EAA early awareness and alert

Table 4

Statistic		95% CIs	
		Sensitivity	66.7
Specificity	77.1	62.7	88.0
PPV	15.4	1.9	45.4
NPV	97.4	86.2	99.9

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Table 3: ATC group L “Cancer”

		Sales Impact		
		>€4 million	≤€4 million	Total
EAA System Prioritization	Prioritized	12	22	34
	Not prioritized	0	32	32
	Total	12	54	66

EAA early awareness and alert

Table 4

Statistic		95% CIs	
		Sensitivity	100.0
Specificity	59.3	45.0	72.4
PPV	35.3	19.7	53.5
NPV	100.0	89.1	100.0

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Table 3: Threshold 2M

		Sales Impact		
		>€2 million	≤€2 million	Total
EAA System Prioritization	Prioritized	24	49	73
	Not prioritized	10	170	180
	Total	34	219	253

EAA early awareness and alert

Table 4

Statistic		95% CIs	
		Sensitivity	70.6
Specificity	77.6	71.5	83.0
PPV	32.9	22.3	44.9
NPV	94.4	90.0	97.3

CI confidence interval; PPV positive predictive value; NPV negative predictive value

Table 3: Threshold 8M

		Sales Impact		
		>€8 million	≤€8 million	Total
EAA System Prioritization	Prioritized	11	62	73
	Not prioritized	1	179	180
	Total	12	241	253

EAA early awareness and alert


Table 4

Statistic		95% CIs	
		Sensitivity	91.7
Specificity	74.3	68.3	79.7
PPV	15.1	7.8	25.4
NPV	99.4	96.9	100.0

CI confidence interval; PPV positive predictive value; NP

Figures

Fig 1 – Study population and early assessment report selection flowchart



EPAR European public assessment reports; MA marketing authorization; EAA early awareness and alert; NAS new active substance; KAS known active substance